Formycon AG
Works in Cardiovascular · Dermatology · Metabolic & endocrine · Oncology · Ophthalmology · Respiratory
Formycon AG is a clinical trial sponsor. It has 1 active clinical trial with 96 planned participants, across 6 therapeutic areas. Since 2021 it has completed 2 trials and stopped 1 early.
Trial track record · since 2021
Pipeline · 1 active trial
| Stage | Trial | Status |
|---|---|---|
On the market
2 approved drug applications with a product on the market.
Questions about Formycon AG
Formycon AG is lead sponsor of 1 active clinical trial on ClinicalTrials.gov, with 96 planned participants, in Cardiovascular, Dermatology, Metabolic & endocrine, Oncology and other areas. Since 2021 it has completed 2 trials and stopped 1 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Formycon AG; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2025-09-04.
Approve Suite is not affiliated with Formycon AG.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.